

08/05/98



JP551 U.S. PTO
09/129603
08/05/98

UTILITY PATENT APPLICATION TRANSMITTAL

Only for new nonprovisional applications under 37 CFR 1.53(b)

Attorney Docket No.

766.25

First Named Inventor or Application Identifier

TETSUYOSHI ISHIWATA

Express Mail Label No.

APPLICATION ELEMENTS

MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)

2. ☒ Specification Total Pages 56

3. ☒ Drawing(s) (35 USC 113) Total Sheets 1

4. ☒ Oath or Declaration Total Pages 3

a. ☐ Newly executed (original or copy)

b. ☒ Unexecuted for information purposes

c. ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]

i. ☐ **DELETION OF INVENTOR(S)**
Signed Statement attached deleting
inventor(s) named in the prior application,
see 37 CFR 1.63(d)(2) and 1.33(b).

5. ☐ Incorporation By Reference (useable if Box 4c is checked)
The entire disclosure of the prior application, from which a copy
of the oath or declaration is supplied under Box 4c, is considered
as being part of the disclosure of the accompanying application
and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

a. ☐ Computer Readable Copy

b. ☒ Paper Copy (identical to computer copy)

c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & document(s))

9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorney

10. ☐ English Translation Document (if applicable)

11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations

12. ☐ Preliminary Amendment

13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

14. ☐ Small Entity Statement filed in prior application
Statement(s) Status still proper and desired

15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. ☐ Other: _____

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No. PCT / JP97/04469

18. CORRESPONDENCE ADDRESS

☒ Customer Number or Bar Code Label 05514 (Insert Customer No. or Attach bar code label here) or ☐ Correspondence address below

NAME

Address

City

State

Zip Code

Country

Telephone

Fax



CLAIMS	(1) FOR	(2) NUMBER FILED	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(c))	44-20 =	24	X \$ 22.00 =	\$528.00
	INDEPENDENT CLAIMS (37 cfr 1.16(b))	1-3 =	0	X \$ 82.00 =	\$0.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d))			\$270.00 =	\$270.00
				BASIC FEE (37 CFR 1.16(a))	\$790.00
			Total of above Calculations =		\$1588.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				
	TOTAL =				\$1588.00

19. Small entity status


- a. ☐ A Small entity statement is enclosed
- b. ☐ A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- c. ☐ Is no longer claimed.

20. ☒ A check in the amount of \$ 1588.00 to cover the filing fee is enclosed.

21. ☐ A check in the amount of \$ _____ to cover the recordal fee is enclosed.

22. The Commissioner is hereby authorized to credit overpayments or charge the following fees to Deposit Account No. 06-1205:

- a. ☒ Fees required under 37 CFR 1.16.
- b. ☒ Fees required under 37 CFR 1.17.
- c. ☐ Fees required under 37 CFR 1.18.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED	
NAME	Lawrence S. Perry
SIGNATURE	
DATE	August 5, 1998

NOVEL PROTEIN

CROSS-REFERENCE TO RELATED APPLICATION

This is a continuation-in-part application of PCT/JP97/04469 filed on December 5, 1997.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a novel protein whose expression level fluctuates in leukocytes of IgA nephropathy patients in comparison with leukocytes of healthy persons, an antibody against the protein, DNA encoding the protein, methods for detecting the protein using the antibody, mRNA and DNA using a primer comprising a complementary nucleotide sequence to the DNA, and diagnosis and treatment of IgA nephropathy.

2. Brief Description of the Background Art

IgA nephropathy is a chronic glomerulonephritis which is characterized in that an IgA immune complex considered to be originated from blood deposits in glomerulus of the kidney. In Japan, the IgA nephropathy occupies 30% or more of primary renal diseases, and is the most common renal disease. Moreover, 15 to 30% of the patients with IgA nephropathy achieve renal failure

due to poor prognosis. However, since the underlying cause of IgA nephropathy is still unclear, a fundamental therapeutic method has not been found. Additionally, definite diagnosis of IgA nephropathy imposes heavy burden on patients, because the method is carried out by removing a portion of the kidney by biopsy and recognizing deposition of the IgA immune complex in mesangium by means of an immunological staining.

It has been reported that about 50% of the patients with IgA nephropathy have a high blood IgA level [*Diseases of the Kidney*, 5th edition (1993), *Nephron*, 29, 170 (1981)]. It is considered that B cells relate to the production of IgA in blood and T cells relate to the regulation of the production. Furthermore, it has been reported that the production of cytokine, such as interleukin 4, interleukin 5, interleukin 6 or TGF- β (transforming growth factor- β), is high in peripheral T cells of IgA nephropathy patients in comparison with healthy persons [*Clinical & Experimental Immunology*, 103, 125 (1996), *Kidney International*, 46, 862 (1994))] and that integrin, such as VLA (very late activation)-4 and VLA-5, are strongly activated in peripheral lymphocytes of IgA nephropathy patients [*Nephrology, Dialysis, Transplantation*, 10, 1342 (1995)].

On the basis of these facts, it is considered that, in IgA nephropathy, excessive IgA is produced due to abnormality in the immune system, the resulting IgA immune complex in blood deposits on the glomerulus, and the complement system is activated on the deposited IgA immune complex and the like to exert influence and cause disorders of the glomerulus. However, the cause of IgA nephropathy has not yet been determined.

SUMMARY OF THE INVENTION

Elucidation of the cause of IgA nephropathy, as well as a treatment or diagnosis which can reduce a burden on patients are long-sought. The present invention provides a novel protein which has been determined to have increased expression level in leukocytes of IgA nephropathy patients, as well as an antibody against the protein, DNA encoding the protein, methods for detecting the protein using the antibody, mRNA and DNA using the oligonucleotide comprising a complementary nucleotide sequence to the DNA, and diagnostic and therapeutic agents of IgA nephropathy.

The present invention relates to a protein comprising the amino acid sequence represented by SEQ ID NO:2; DNA encoding the protein of the present invention; DNA which comprises the nucleotide sequence represented

by SEQ ID NO:1; and DNA which hybridizes with the DNA comprising the above nucleotide sequence under stringent conditions. Furthermore, the present invention relates to a recombinant vector which comprises the DNA and a vector; a transformant obtained by introducing the recombinant vector into a host cell; and a process for producing the protein, comprising culturing the transformant in a medium to produce and accumulate the protein of the present invention in the culture, and recovering the protein from the resulting culture.

Moreover, the present invention relates to a method for detecting the mRNA derived from the protein of the present invention using an oligonucleotide comprising a portion of the nucleotide sequence of the DNA of the present invention or a portion of the nucleotide sequence complementary to the DNA, for example, the oligonucleotide represented by SEQ ID NO:6 or NO:7; and IgA nephropathy diagnostic agents comprising the oligonucleotide.

Also, the present invention relates to a method for inhibiting expression of the protein of the present invention using an oligonucleotide comprising a portion of the nucleotide sequence of the DNA of the present invention or a portion of the nucleotide sequence complementary to the DNA, for example, the

oligonucleotide represented by SEQ ID NO:6 or NO:7; and IgA nephropathy therapeutic agents comprising the oligonucleotide.

Additionally, the present invention relates to an antibody which specifically reacts with the protein of the present invention; a method for immunologically detecting the protein of the present invention using the antibody of the present invention; and IgA nephropathy diagnostic and therapeutic agents comprising the antibody.

BRIEF EXPLANATION OF THE DRAWINGS

Fig. 1 shows an autoradiograph of the Northern blot of KIAA0235 in human tissue and cell in Example 5. Both A and B are results of human tissue, wherein A represents the autoradiograph of the filter blotting each RNA of 1: pancreas, 2: kidney, 3: skeletal muscle, 4: liver, 5: lung, 6: placenta, 7: brain, and 8: heart, and B represents the autoradiograph of the filter blotting each RNA of 1: peripheral leukocyte, 2: colon, 3: small intestine, 4: ovary, 5: testis, 6: prostate, 7: thymus, and 8: spleen. C is a result of human cell line, which represents the autoradiograph of the filter blotting the RNA of 1: HeLa and 2: KG-1. Lines at the leftmost end of A correspond to the RNA marker positions

indicating 9.5 kb, 7.5 kb, 4.4 kb, 2.4 kb and 1.35 kb from the top.

Fig. 2 shows the detection results of RT-PCR of KIAA0235 against the leukocyte of IgA nephropathy patients and healthy persons by the fluorimager in Example 4. 1 to 5 show the RT-PCR of the leukocyte of 5 healthy persons, 6 to 10 show that of 5 IgA nephropathy patients, and C shows PCR using as the template the plasmid to which the amplified fragment of the KIAA0235 cDNA obtained by differential display is introduced as the positive control.

DETAILED DESCRIPTION OF THE INVENTION

This application is based on Japanese application No. 8-325752 filed on December 5, 1996 and PCT/JP97/04469 filed on December 5, 1997, the entire contents of which are incorporated hereinto by reference.

The protein of the present invention includes, for example, a protein comprising the amino acid sequence represented by SEQ ID NO:2. The DNA of the present invention includes a DNA sequence encoding the protein of the present invention, a DNA sequence comprising the nucleotide sequence represented by SEQ ID NO:1, a DNA sequence which hybridizes with the DNA under stringent conditions, and the like.

The DNA encoding the protein of the present invention includes DNAs having a nucleotide sequence different from the nucleotide sequence represented by SEQ ID NO:1 because generally there are various genetic codes per one amino acid. Those of ordinary skill in this art are well-aware of how to substitute one or more degenerate codons to create an equivalent DNA encoding the same protein sequence. This includes, for example, selecting degenerate codons which may be more common in a particular expression system, such as yeast.

Furthermore, the DNA which hybridizes under stringent conditions with a DNA comprising a nucleotide sequence represented by SEQ ID NO:1 means a DNA in which a mutation, such as substitution, deletion, insertion, addition and the like, is introduced at least one portion within the range that the inherent activities of the protein are not lost, and a DNA which is obtained by colony hybridization or plaque hybridization [*Molecular Cloning, A Laboratory Manual*, Second Edition (edited by Sambrook, Fritsch and Maniatis, Cold Spring Harbor Laboratory Press (1989)) (referred to as "*Molecular Cloning, A Laboratory Manual*, 2nd ed." hereinafter) using, as a probe, a DNA comprising a nucleotide sequence represented by SEQ ID NO:1 or a fragment thereof.

The preparation and expression of the DNA encoding the novel protein of the present invention is carried out according to the process described in *Molecular Cloning, A Laboratory Manual*, 2nd ed., *Current Protocols in Molecular Biology, Supplement 1 to 34* (edited by Ausubel, Brent, Kingston, Moore, Seidman, Smith and Struhl, published by Green Publishing Associates and Wiley-Interscience, 1987-1996 edition) (referred to as "*Current Protocols in Molecular Biology, Supplement 1 to 34*"), and the like.

In the present invention, in order to obtain a novel protein, taking note of the difference in the expression quantity of mRNA in leukocytes between patients with IgA nephropathy and healthy persons, the differential display method [*FEBS Letters*, 351, 231 (1994)] is used. The differential display method is a method in which cloning of a novel gene is carried out using pattern of expression as an index. That is, an amplified cDNA fragment of a novel gene whose expression level increases or decreases significantly in leukocytes of a patient with IgA nephropathy as compared with leukocytes of a healthy person is obtained by subjecting total RNA or mRNA extracted from cells to the polymerase chain reaction (PCR) using various primers. At the same time, a cDNA library is constructed from human

undifferentiated myeloid cell line KG-1, and all nucleotide sequences of cDNA of respective clone are determined to form a database beforehand. The homology between the nucleotide sequence of the clone therein and the above-described amplified cDNA fragment is identified, and a novel full-length cDNA is obtained. This method is described below.

Examples of the method for the preparation of a total RNA from leukocytes of patients with IgA nephropathy and leukocytes of healthy persons include guanidine thiocyanate-cesium trifluoroacetate method [*Methods in Enzymol.*, 154, 3 (1987)], the AGPC method (Jikken Igaku, 2, 1937 (1991)), RNeasy kit for recovering RNA (produced by QIAGEN), and the like.

Examples of the method for preparing poly(A)⁺ RNA from the total RNA include oligo(dT)-immobilized cellulose column method (*Molecular Cloning, A Laboratory Manual*, 2nd ed.) and the like. Also, examples of the kit for preparing mRNA from leukocytes of patients with IgA nephropathy and leukocytes of healthy persons include Fast Track mRNA Isolation Kit (manufactured by Invitrogen), Quick Prep mRNA Purification Kit (manufactured by Pharmacia), and the like.

Using an anchor primer, cDNA is synthesized in the usual way from the RNA extracted by the above-

described method from leukocytes of a patient with IgA nephropathy or leukocytes of a healthy person, and PCR is carried out using an anchor primer having a 5'-end labeled with fluorescence and an arbitrary primer. The anchor primer is a primer in which an oligonucleotide of adenine, guanine or cytosine, excluding thymidine, is added to the 3'-end of an oligo(dT) sequence which hybridizes with a 3'-end poly(A) sequence of mRNA. The arbitrary primer is typically an oligonucleotide which amplifies various cDNA sequences and can yield a large number of amplified cDNA fragments by a single reaction. Preferably, the oligonucleotide has a length of about 10 mer.

After the PCR, each of the amplified cDNA is subjected to polyacrylamide gel electrophoresis, and the electrophoresis pattern of the amplified cDNA fragment is compared by detecting the fluorescence with a fluorimager. The cDNA fragment which can be amplified by only leukocytes of a patient with IgA nephropathy is extracted from the gel, the amplified cDNA fragment is inserted into a vector, and the nucleotide sequence of the DNA is determined by a usually used nucleotide sequence analyzing method such as the dideoxy method of Sanger et al. [Proc. Natl. Acad. Sci. USA, 74, 5463 (1977)], or like.

Examples of the vector to which the DNA fragment is inserted include pDIRECT [Nucleic Acids Research, 18, 6069 (1990)], pPCR-Script Amp SK(+) [manufactured by Stratagene, Strategies, 5, 6264 (1992)], pT7Blue (manufactured by Novagen), pCR II [manufactured by Invitrogen, Biotechnology, 2, 657 (1991)], pCR-TRAP (manufactured by Genehunter), pNotA_T (manufactured by 5'→3') and the like.

The analysis of the nucleotide sequence is carried out by using a nucleotide sequence automatic analyzer, such as 373A-DNA sequencer (manufactured by Applied Biosystems), and the like.

Full-length cDNA can be obtained by carrying out screening according to hybridization using the above-described amplified cDNA fragment as the probe and various cDNA libraries. Also, as in the present invention, a clone having the full-length cDNA can be obtained by constructing a cDNA library in advance, determining all nucleotide sequences of a respective clone to form a data base, and then screening a clone having the nucleotide sequence of the above-described amplified cDNA fragment. The method for preparing a cDNA library will be described.

Examples of the method for the preparation of the cDNA library include methods described in Molecular

Cloning, A Laboratory Manual, 2nd. ed., or Current Protocols in Molecular Biology, Supplement 1 to 34, methods using a commercially available kit, such as Super Script™ Plasmid System for cDNA Synthesis and Plasmid Cloning (manufactured by Life Technologies) or ZAP-cDNA Synthesis Kit (manufactured by Stratagene), and the like.

In the preparation of the cDNA library, the vector to which the cDNA, synthesized using mRNA extracted from human undifferentiated myeloid cell line KG-1 as a template, is inserted may be any vector so long as the cDNA can be inserted thereto. Examples include ZAP Express [Strategies, 5, 58 (1992)], pBluescript II SK(+) [Nucleic Acids Research, 17, 9494 (1989)], λ zap II (manufactured by Stratagene), λ gt10, λ gt11 [DNA Cloning, A Practical Approach, 1, 49 (1985)], Lambda BlueMid (manufactured by Clontech), λ ExCell, pT7T318U (manufactured by Pharmacia), pcD2 [Mol. Cell. Biol., 3, 280 (1983)], pUC18 [Gene, 33, 103 (1985)], and the like.

With regard to the *Escherichia coli* for introducing the cDNA library constituted by the vector, any microorganism belonging to *Escherichia coli* can be used so long as the introduction, expression and maintenance of the cDNA library can be conducted.

Examples include *Escherichia coli* XL1-Blue MRF' [Strategies, 5, 81 (1992)], *Escherichia coli* C600 [Genetics, 39, 440 (1954)], *Escherichia coli* Y1088, *Escherichia coli* Y1090 [Science, 222, 778 (1983)], *Escherichia coli* NM522 [J. Mol. Biol., 166, 1 (1983)], *Escherichia coli* K802 [J. Mol. Biol., 16, 118 (1966)], *Escherichia coli* JM105 [Gene, 38, 275 (1985)], and the like.

The cDNA can be also obtained without preparing a cDNA library by the 5'-RACE (rapid amplification of cDNA ends) and 3'-RACE [Proc. Natl. Acad. Sci. USA, 85, 8998 (1988)] in which adapters are added to both ends of the cDNA and then PCR is carried out using primers based on the nucleotide sequence of the adapter and the nucleotide sequence of the amplified fragment. Alternatively, the cDNA can be obtained by PCR based on the nucleotide sequence represented by SEQ ID NO:1 or a chemical synthesis method using a DNA synthesizer.

A cDNA clone can be selected from the cDNA library according to a colony hybridization or plaque hybridization method (Molecular Cloning, A Laboratory Manual, 2nd ed.) using a probe labeled with an isotope or fluorescence. The cDNA may be also prepared according to the polymerase chain reaction (PCR) [Molecular Cloning, A Laboratory Manual, 2nd ed. or

Current Protocols in Molecular Biology, Supplement 1 to 34] by preparing a primer and using, as a template, cDNA synthesized from poly (A)⁺RNA or mRNA, or cDNA library.

The nucleotide sequence of the DNA can be determined by cleaving the cDNA clone selected by the above method with an appropriate restriction enzyme, cloning to a plasmid, such as pBluescript KS(+) (manufactured by Stratagene) or the like, and then analyzing by a conventional nucleotide sequence analysis method, such as dideoxy method of Sanger et al. [Proc. Natl. Acad. Sci., U.S.A., 74, 5463 (1977)] or the like. The nucleotide sequence can be analyzed by using a nucleotide sequence automatic analyzer, such as 373A⁺DNA sequencer (manufactured by Applied Biosystems) or the like.

A transformant which expresses the protein of the present invention can be obtained by preparing a transformed vector to which the full-length DNA prepared according to the above method is inserted into a downstream site of the promoter in an appropriate vector.

As the host cell, any bacterium, yeast, animal cell, insect cell, and the like, can be used so long as they can express the gene of interest. Examples of the bacterium include bacteria belonging to the genus *Escherichia*, *Serratia*, *Corynebacterium*, *Brevibacterium*,

Pseudomonas, *Bacillus*, *Microbacterium* and the like, for example, *Escherichia coli*, *Bacillus subtilis*, *Bacillus amyloliquefaciens*, *Brevibacterium flavum*, *Brevibacterium lactofermentum*, *Corynebacterium glutamicum*, *Microbacterium ammoniaphilum*, and the like. Examples of the yeast include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces lactis*, *Trichosporon pullulans*, *Schwanniomyces alluvius* and the like. Examples of the animal cell include human Namalwa cell, monkey COS cell, Chinese hamster CHO cell, and the like. Examples of the insect cell include *Spodoptera frugiperda* oocytes Sf9 and Sf21 (*Baculovirus Expression Vectors, A Laboratory Manual*, Oreilly, Miller and Luckow, W.H. Freeman and Company, New York, (1992) (referred to as "*Baculovirus Expression Vectors, A Laboratory Manual*" hereinafter)), *Trichoplusia ni* oocyte Tn5 (High 5, manufactured by Pharmigen), and the like.

Any vector can be used as the vector to which the DNA of the present invention is inserted so long as it can introduce the DNA and drive the expression in the host cell.

When a bacterium, such as *Escherichia coli*, is used as the host cell, it is preferred that the vector is constituted by a promoter, a ribosome binding sequence, the DNA of the present invention and a

transcription termination sequence. A promoter controlling gene may be also contained.

Examples of the expression vector include pKYP10 (Japanese Published Unexamined Patent Application No. 110600/83), pLSA1 [Agric. Biol. Chem., 53, 277 (1989)], pGEL1 [Proc. Natl. Acad. Sci. USA, 82, 4306 (1985)], and the like.

With regard to the promoter, any promoter can be used so long as it can drive the expression in the host cell. Examples include promoters originated from *Escherichia coli*, phage and the like (for example, trp promoter (Ptrp), lac promoter (Plac), T7 lac promoter, PL promoter, PR promoter, and the like). Also, artificially designed and modified promoters, such as a promoter in which two Ptrp are linked in series (Ptrp × 2), tac promoter, and the like, can be used.

With regard to the ribosome binding sequence, it is preferred to use a plasmid in which the space between Shine-Dalgarno sequence (referred to as "SD sequence" hereinafter) and the initiation codon is adjusted to an appropriate distance (for example, 6 to 18 bases).

With regard to the recombinant vector of the present invention, it is preferred to substitute a suitable nucleotide in order that the nucleotide

sequence of the DNA of the present invention forms a codon suitable for the expression of a host cell.

The transcription termination sequence is not always necessary for the recombinant vector of the present invention. However, it is preferred to arrange the transcription terminating sequence just downstream of the structural gene.

With regard to the method for the introduction of the recombinant vector to the bacterium, any one of the known methods for introducing DNA into the bacterium, such as a method in which calcium ion is used [Proc. Natl. Acad. Sci. USA, 69, 2110 (1972)], a protoplast method (Japanese Published Unexamined Patent Application No. 2483942/88), and the like, can be used.

When yeast is used as the host cell, YEp13 (ATCC 37115), YEp24 (ATCC 37051), YCp50 (ATCC 37419), or the like is used as the expression vector. Any promoter can be used so long as it can drive the expression in yeast. Examples include promoters of genes in the glycolysis system (for example, hexosekinase, and the like), gal 1 promoter, gal 10 promoter, heat shock protein promoter, MFu1 promoter, CUP 1 promoter and the like.

With regard to the method for the introduction of the recombinant vector, any one of known methods for introducing DNA into yeast, such as an electroporation

method [Methods. Enzymol., 194, 182-187 (1990)], a spheroplast method [Proc. Natl. Acad. Sci. USA, 84, 1929-1933 (1978)], a lithium acetate method [J. Bacteriol., 153, 163-168 (1983)], and the like can be used.

When animal cells are used as the host cells, pAGE107 [Japanese Published Unexamined Patent Application No. 22979/91; Cytotechnology, 3, 133 (1990)], pAS3-3 (Japanese Published Unexamined Patent Application No. 227075/90), pAMoERC3Sc, pcDM8 [Nature, 329, 840 (1987)], pcDNAI/Amp, pcDNAI (both manufactured by Funakoshi), and the like can be exemplified as the expression vector. Any promoter can be used so long as it can drive the expression in animal cell. Examples include a promoter of IE (immediate early) gene of cytomegalovirus (CMV), a promoter of SV40 or metallothionein, and the like. Also, the enhancer of the IE gene of human CMV may be used together with the promoter.

With regard to the method for the introduction of the recombinant vector into animal cells, any one of the known methods for introducing DNA into animal cells, such as an electroporation method [Cytotechnology, 3, 133 (1990)], a calcium phosphate method (Japanese Published Unexamined Patent Application No. 227075/90),

a lipofection method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)], and the like can be used.

When an insect cell is used as the host cell, the protein can be expressed by known methods described in, for example, Current Protocols in Molecular Biology, supplement 1-34; Baculovirus Expression Vectors, A Laboratory Manual; or the like. That is, a recombinant gene transfer vector and baculovirus are simultaneously introduced into an insect cell to obtain a recombinant virus in an insect cell culture supernatant, and then insect cells are infected with the thus obtained recombinant virus to obtain protein expression insect cell.

Examples of the gene transfer vector include pVL1392, pVL1393, pBlueBacIII (all manufactured by Invitrogen), and the like.

Examples of the baculovirus include Autographa californica nuclear polyhedrosis virus with which insects of the family Barathra are infected, and the like.

The method for the co-transfer of the above-described recombinant gene transfer vector and the above-described baculovirus for the preparation of the recombinant virus include a calcium phosphate method (Japanese Published Unexamined Patent Application No.

227075/90), a lipofection method [Proc. Natl. Acad. Sci. USA, 84, 7413 (1987)], and the like.

With regard to the gene expression method, a secreted protein production, a fusion protein expression and the like can be effected in accordance with the method described in J. Sambrook et al. (*Molecular Cloning*, 2nd ed.) in addition to the direct expression.

When expressed in a yeast, an animal cell or a insect cell, a protein to which sugar or sugar chain is added by exo- or endo-glycosidase can be obtained.

The protein of the present invention can be produced by culturing the thus obtained transformant in a culture medium to produce and accumulate the protein of the present invention, and recovering the protein from the resulting culture. Culturing of the transformant of the present invention in a culture medium is carried out in accordance with a usual method used in culturing of host cells.

The medium for culturing the transformant obtained by using as the host cell a microorganism, such as *Escherichia coli*, yeast or the like, may be either a natural medium or a synthetic medium, so long as it contains a suitable carbon source, a suitable nitrogen source, and a suitable inorganic salt and the like, which enables culturing the transformant efficiently.

Examples of the carbon source include carbohydrates (for example, glucose, fructose, sucrose, molasses, starch, starch hydrolysate, and the like), organic acids (for example, acetic acid, propionic acid, and the like), and alcohols (for example, ethanol, propanol, and the like).

Examples of the nitrogen source include ammonia, various ammonium salts of inorganic acids or organic acids (for example, ammonium chloride, ammonium sulfate, ammonium acetate, ammonium phosphate, and the like), other nitrogen-containing compounds, peptone, meat extract, yeast extract, corn steep liquor, casein hydrolysate, soybean meal and soybean meal hydrolysate, various fermented cells and hydrolysates thereof, and the like.

Examples of inorganic substance include potassium dihydrogen phosphate, dipotassium hydrogen phosphate, magnesium phosphate, magnesium sulfate, sodium chloride, ferrous sulfate, manganese sulfate, copper sulfate, calcium carbonate, and the like.

The culturing is carried out under aerobic conditions by means of shaking, aeration stirring or the like at 15 to 45°C for 16 to 96 hours. The pH of the medium is maintained at 3.0 to 9.0 during the culturing. Adjustment of the medium pH is carried out using an

inorganic or organic acid, an alkali solution, urea, calcium carbonate, ammonia and the like.

Also, antibiotics (for example, ampicillin, tetracycline, and the like) may be added to the medium during the culturing as occasion demands.

When a microorganism transformed with an expression vector containing an inducible promoter is cultured, an inducer may be added to the medium as occasion demands. For example, isopropyl- β -D-thiogalactopyranoside (IPTG) or the like may be added to the medium when a microorganism transformed with an expression vector containing lac promoter is cultured, or indoleacrylic acid (IAA) or the like may be added thereto when a microorganism transformed with an expression vector containing trp promoter is cultured.

Examples of the medium used in the culturing of a transformant obtained using an animal cell as the host cell include RPMI 1640 medium, Eagle's MEM medium, and any one of these media further supplemented with fetal calf serum. The culturing is carried out generally at a temperature of 35 to 37°C for a period of 3 to 7 days in the presence of 5% CO₂. As occasion demands, antibiotics (for example, kanamycin, penicillin, and the like) may be added to the medium during the culturing.

Examples of the medium used in the culturing of a transformant obtained using an insect cell as the host cell include TNM-FH medium (manufactured by Pharmingen), Sf900 II SFM (manufactured by Life Technologies), ExCell 400 or ExCell 405 (both manufactured by JRH Biosciences), and the like. The culturing is carried out generally at a temperature of 25 to 30°C for a period of 1 to 4 days. Additionally, antibiotics (for example, gentamicin, and the like) may be added to the medium during the culturing as occasion demands.

When the protein of the present invention is expressed in a dissolved state inside the cells, the cells after completion of the culturing are recovered by centrifugation, suspended in an aqueous buffer and then disrupted by ultrasonic, French press or the like to obtain the protein from a supernatant fluid prepared by centrifugation. Also, when the protein forms an inclusion body, the inclusion body is solubilized using a protein denaturing agent, and then the solubilized solution is diluted to or dialyzed against a solution containing no protein denaturing agent or a dilute solution containing a protein denaturing agent in such a concentration that the protein is not denatured in order to form a renatured protein.

When the protein of the present invention or a derivative thereof, such as a sugar-modified product or the like, is secreted outside the cells, the protein or the derivative, such as a sugar-modified product or the like, can be recovered from the culture supernatant. That is, the isolation and purification can be conducted by using isolation steps, such as solvent extraction, fractional precipitation by an organic solvent, salting-out, dialysis, centrifugation, ultrafiltration, ion exchange chromatography, gel filtration chromatography, hydrophobic interaction chromatography, affinity chromatography, reverse phase chromatography, crystallization, electrophoresis, and the like, alone or as a combination thereof.

Furthermore, the protein of the present invention can be prepared according to a chemical synthesis method based on the amino acid sequence represented by SEQ ID NO:2.

Examples of a method for detecting the mRNA of a novel protein using the oligonucleotide based on the nucleotide sequence of the DNA of the present invention include Northern hybridization [*Molecular Cloning, A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press (1989)], PCR [*PCR Protocols*, Academic Press (1990)], and the like. Particularly, RT (Reverse

Transcribed)-PCR is simple and easy and can therefore be applied to the diagnosis of IgA nephropathy. Specifically, the amplified fragment is detected by collecting blood from human to recover leukocyte, transforming the RNA isolated therefrom into cDNA using an oligo(dT) primer and a reverse transcriptase into, and conducting PCR using a pair of oligonucleotide primers corresponding to the mRNA to be detected.

Examples of the oligonucleotide primers include a sense primer corresponding to the 5'-end side nucleotide sequence, and an antisense primer corresponding to the 3'-end side nucleotide sequence, of a portion of the mRNA to be detected. In this case, the nucleic acid corresponding to uracil in mRNA corresponds to thymidine in the oligonucleotide primer.

As the sense primer and antisense primer, it is preferred to use oligonucleotides in which melting point (T_m) and the number of bases are not significantly different from each other. Preferably, the base number is 15 to 40 mer.

The nucleotide sequence moiety to be amplified using the above oligonucleotide primer may be any nucleotide sequence region of the mRNA, but a nucleotide sequence region which has a length of 50 bp to 2 kbp and

does not contain a sequence rich in a repeating sequence or GC (guanine-cytosine) bases is preferred.

Furthermore, the expression of the protein can be inhibited by repressing the transcription of DNA or translation of mRNA using an antisense RNA/DNA [Chemistry, 46, 681 (1991), Biotechnology, 9, 358 (1992)]. The inhibition of production of the protein using anti-sense RNA/DNA technology can be carried out by designing and preparing an oligonucleotide based on the nucleotide sequence of a portion of the DNA encoding the protein of the present invention, preferably that of 10 to 50 bases positioned in the translation initiation site, and administering it in vivo. As the nucleotide sequence of the synthetic oligonucleotide, those which partially comprises the nucleotide sequence of the anti-sense chain of the DNA encoding of the protein of the present invention, or those which have been modified to the extent not to lose the activity of inhibiting the expression of the protein activity can be used. As oligonucleotide, DNA, RNA or their derivatives, such as methyl or phosphorothioate derivatives, can be used.

The antibody can be produced by immunizing an animal using the protein of the present invention as an antigen or a peptide, chemically synthesized based on the amino acid sequence represented by SEQ ID NO:2 which

is a protein of the present invention. A monoclonal antibody to the protein of the present invention can be prepared by preparing a hybridoma through fusion of the antibody producing cells with myeloma cells of an animal and culturing the hybridoma, or administering the hybridoma to the animal to induce ascites tumor in the animal, and then isolating and purifying it from the culture medium or ascitic fluid. Also, a polyclonal antibody to the protein of the present invention can be prepared by isolating the immune serum of the immune animal.

Using the antibody of the present invention, the IgA nephropathy-related protein can be detected or determined immunologically.

Examples of the immunological detection method include ELISA method using a microtiter plate, fluorescent antibody technique, western blot technique, immunohistochemical staining and the like.

Examples of the immunological determination method include sandwich ELISA method in which, among antibodies which react with the protein of the present invention in solution, two monoclonal antibodies having different epitopes are used and radioimmunoassay method in which the protein of the present invention labeled with radioactive isotope, such as ^{125}I or the like, and

an antibody which recognizes the protein of the present invention are used.

Using the antibody of the present invention, the presence or absence of IgA nephropathy in a person to be inspected can be diagnosed by immunologically detecting or determining an IgA nephropathy-related protein in leukocytes collected from a healthy person and the person to be inspected, comparing its amounts in the healthy person and person to be inspected and then examining the quantitative fluctuation. As a specific sample to be tested, leukocytes separated from peripheral blood samples of a healthy person and a person to be inspected can be used. Additionally, when the IgA nephropathy-related protein to be detected is a protein secreted from leukocytes, the presence or absence of IgA nephropathy in a person to be inspected can be detected and diagnosed by immunologically detecting or determining the protein in blood plasma samples collected from a healthy person and the person to be inspected, comparing its amounts in the healthy person and person to be inspected and then examining its quantitative fluctuation.

The antibody of the present invention can be applied to the treatment or prevention of IgA nephropathy.

When the DNA, protein, oligonucleotide and antibody is used for the diagnosis, treatment or prevention of IgA nephropathy, a diagnostically or pharmacologically acceptable carrier may be added.

EXAMPLES

Examples of the present invention are given below by way of illustration and not by way of limitation.

Example 1 Preparation of human undifferentiated myeloid cell line KG-1cDNA library

(1) Preparation of poly (A)⁺RNA from KG-1 cell

KG-1 (ATCC CCL246), human undifferentiated myeloid cell line, was cultivated in the Iskov modified Dulbecco's medium (manufactured by Gibco BRL) to collect cells as pellet. To 1 ml of the cell pellet, 2.8 ml of a cytolytic solution [140 mM NaCl, 1.5 mM MgCl₂, 10 mM tris(hydroxymethyl)aminomethane (Tris)-HCl (pH 8.5), 0.5% of Nonidet P-40] and 0.2 ml of 400 mM vanadyl sulfuric acid ribonucleotide complex were added. The cells were dissolved in the solution on the ice, superposed on 1 ml of a saccharose solution [140 mM NaCl, 1.5 mM MgCl₂, 10 mM Tris-HCl (pH 8.5), 1% Nonidet P-40, 24% saccharose], and centrifuged at 2°C for 30 minutes at 30,000 rpm. To 4 ml of the supernatant containing RNA, 4 ml of an enzymatic reaction buffer [200 mM Tris-

HCl (pH 7.5), 25 mM disodium ethylenediaminetetraacetate (EDTA), 300 mM NaCl, 2% lauryl sodium sulfate (SDS)] and 200 μ l of 10 mg/ml proteinase K were added and allowed to react for 5 minutes at room temperature. To this reaction mixture, phenol extraction and chloroform extraction were carried out, and ethanol precipitation were carried out to recover RNA. After RNA was sufficiently dissolved in 4.5 ml of a buffer solution [20 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 0.1% SDS], it was heated at 70°C for 5 minutes and chilled quickly, and then 0.5 ml of 5 M LiCl was added. The solution was centrifuged at 2°C for 10 minutes at 8,000 rpm, the supernatant was heated at 70°C for 5 minutes and chilled quickly, and then applied to an oligo d(T) cellulose column [Pasteur pipet charged with oligo dT cellulose (manufactured by Sigma)] which had been equilibrated with an absorption buffer [20 mM Tris-HCl (pH 7.5), 500 mM LiCl, 0.1 mM EDTA, 0.1% SDS]. The flow-through from the column was heated at 70°C for 5 minutes and chilled quickly, and then applied to the column for absorbing poly (A)⁺RNA again. The column was washed once with 1 ml of the absorption buffer, 3 times with 1.5 ml of the absorption buffer, 5 times with 1.5 ml of a washing buffer [20 mM Tris-HCl (pH 7.5) and 100 mM LiCl, 0.1 mM EDTA], and eluted with 3 ml of an elution buffer [10 mM

Tris-HCl (pH 7.5), 0.1 mM EDTA] for recovering poly (A)⁺RNA. From 6 ml (2 g) of the cell pellet, 8 mg of total RNA was obtained, and 200 µg of poly (A)⁺RNA was obtained therefrom.

(2) Production of cDNA library

A 8 µl (9.1 µg) portion of poly d(T)-NotI primer represented by SEQ ID NO:3, 32 µl of 5 mM Tris-HCl (pH 8.3) and 120 µl of distilled water were added to the obtained poly (A)⁺RNA 40 µg (40 µl). DNA was synthesized by the method described in *Nucleic Acids Res.*, 12, 4539 (1984). It was heated at 70°C for 10 minutes and chilled quickly, and then 64 µl of 5 × reverse transcriptase reaction buffer [250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 mM MgCl₂], 32 µl of 100 mM dithiothreitol (DTT) and 8 µl of 20 mM dNTP (dATP, dGTP, dTTP, dCTP) were added thereto. After heating at 37°C for 2 minutes, 3,200 units (16 µl) of reverse transcriptase SUPERScript RNase H⁻ Reverse Transcriptase (manufactured by Gibco BRL) were added thereto, and the solution was allowed to react at 37°C for 1 hour to synthesize cDNA. To the reaction mixture, 15 µl of 20 mM dNTP, 60 µl of 100 mM DTT, 16 µl of 15 mM β-nicotinamide dinucleotide and 929 µl of distilled water were added. Thereto further added was 32 units (16 µl) of *E. coli* ribonuclease H (manufactured by Takara Shuzo Co., Ltd.), 256 units (32

μl) of DNA polymerase I (manufactured by Takara Shuzo Co., Ltd.) and 480 units (8 μl) of E. coli DNA ligase (manufactured by Takara Shuzo Co., Ltd.), and allowed to react at 16°C for 2 hours to prepare cDNA double-stranded. T4 DNA polymerase (48 units (24 μl)) was added and allowed to react at 16°C for 5 minute to convert the termini blunt. EDTA (24 μl, 200 mM) was added thereto, and heated at 70°C for 10 minutes to stop the reaction. The reaction mixture was subjected to phenol-chloroform extraction, and then ethanol precipitation was carried out. Additionally, ethanol precipitation was carried out two times to purify the cDNA. The double-stranded cDNA was dissolved in 40 μl of TE buffer [10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0)], and 60 μl of 10 × restriction enzyme reaction buffer [500 mM Tris-HCl (pH 7.5), 100 mM MgCl₂, 10 mM DTT, 1M NaCl, 0.1% Triton X-100, 0.1% bovine serum albumin (BSA)] and 460 μl of distilled water were added thereto, and 320 units (40 μl) of restrictive enzyme NotI (manufactured by Takara Shuzo Co., Ltd.) were added thereto for digestion reaction at 37°C for 2 hours. Moreover, 192 units (24 μl) of NotI were added thereto, and the reaction was carried out at 37°C for 1 hour, and the reaction mixture was heated at 70°C for 3 minutes to stop the reaction. After phenol/chloroform extraction,

ethanol precipitation was carried out, and additionally, ethanol precipitation was carried out two times to purify cDNA. The cDNA was centrifuged at 24,000 rpm for 24 hours with sucrose density gradient of 5 to 30% to separate into the fraction of larger than 6 kb, the fraction of 2 to 6 kb and the fraction of less than 2 kb. The fraction of 2 to 6 kb (0.5 µg) and 0.5 µg of plasmid vector pBluescript SK+ digested by NotI-EcoRV are ligated and introduced into *E. coli* DH10B (manufactured by Gibco) to prepare the cDNA library.

(3) Determination of nucleotide sequence of cDNA of each clone in KG-1cDNA library

The nucleotide sequence of cDNA of each clone in the library was determined using 373 DNA sequencer of Parkin Elmer. As specific reagents and method for the nucleotide sequence determination, Dye Primer Cycle Sequencing FS Ready Reaction Kit of Parkin Elmer were used in accordance with the manual attached to the kit. Thus obtained cDNA nucleotide sequences were collected to create a database.

Example 2 Cloning of cDNA fragment of the novel gene KIAA0235

(1) Preparation of total RNA from leukocytes of IgA nephropathy patients and healthy persons

A 20 ml portion of blood was collected from each of five IgA nephropathy patients and five healthy persons. Each blood sample was mixed with 500 μ l of 1,000 units/ml heparin solution to inhibit coagulation, transferred into a centrifugation tube and then centrifuged at 3,300 rpm for 15 minutes at room temperature, and the resulting intermediate layer buffy coat containing leukocytes was transferred into another centrifugation tube. Thereafter, total RNAs were obtained in accordance with the AGPC method [Experimental Medicine, 9, 1937 (1991)].

(2) Fluorescence differential display using leukocyte total RNAs of IgA nephropathy patients and healthy persons

Distilled water was added to 2.5 μ g of each of the total RNAs to a total volume of 9 μ l, and the solution was mixed with 1 μ l of an anchor primer (nucleotide sequence represented by SEQ ID NO:4, custom-synthesized by Sawady, 50 μ M) whose 5'-end had been fluorescence-labeled with fluorescein isothiocyanate (referred to as "FITC" hereinafter), heated at 70°C for

5 minutes and then immediately cooled on an ice bath. Thereto added were 2 μ l of distilled water, 4 μ l of 5 \times reverse transcriptase reaction buffer, 2 μ l of 100 mM DTT, 1 μ l of 10 mM dNTP and 1 μ l (200 units) of reverse transcriptase SUPERSCRIPT RNase H⁻ Reverse Transcriptase (manufactured by Gibco BRL), the solution was mixed, allowed to react at 25°C for 10 minutes and at 42°C for 50 minutes to synthesize cDNA, and heated at 90°C for 5 minutes to stop the reaction. To the reaction mixture, 80 μ l of TE buffer was added.

To 1 μ l of each synthesized cDNA, 14.7 μ l of distilled water, 2 μ l of 10 \times PCR buffer [100 mM Tris-HCl (pH 8.8), 500 mM KCl, 15 mM MgCl₂, 1% Triton X-100], 0.8 μ l of 2.5 mM dNTP, 0.3 μ l of 50 μ M fluorescent labeling anchor primer FCH, 1 μ l of arbitrary primer OPD-16 (nucleotide sequence represented by SEQ ID NO:5, manufactured by Operon, 10 μ M) and 0.2 μ l of DNA polymerase Gene Taq (manufactured by Nippon Gene Co., Ltd., 5 units/ μ l) were added and set to a thermal cycler. The PCR was effected by carrying out the reaction at 94°C for 3 minutes, 40°C for 5 minutes and 72°C for 5 minutes, subsequently carrying out a total of 27 cycles of the reaction in which one cycle was composed of the steps of 95°C for 15 seconds, 40°C for 2 minutes and 72°C

for 1 minute, and finally carrying out 5 minutes of the reaction at 72°C.

A 3 μ l portion of an electrophoresis sample solution (95% formaldehyde, 0.1% xylene cyanol, 0.1% bromphenol blue) to 4 μ l of each PCR mixture, heated at 95°C for 2 minutes and chilled immediately, and 6% acrylamide gel electrophoresis was conducted at and 1500 V for 2.5 hours. The electrophoresis buffer containing 89 mM Tris, 89 mM boric acid, 2 mM EDTA were used. Gel fluorescence after the electrophoresis was measured by a fluorimager (manufactured by Molecular Dynamics Inc.) for detecting and comparing the PCR amplified fragments. In comparison with 5 cases of the healthy persons, a band which significantly increased in leukocytes of 5 cases of the IgA nephropathy patients was recorded. Furthermore, total RNAs were prepared from other 3 cases of IgA nephropathy patients and 3 cases of healthy persons in the same manner to carry out the differential display in the same manner.

A band of about 200 bands which showed increased fluorescence in both of the above two trials of the differential display was cut off from the gel.

A 38 μ l portion of distilled water, 5 μ l of 10 \times PCR buffer, 4 μ l of 2.5 mM dNTP, non-fluorescence labeling anchor primer NC (sequence listing represented

by SEQ ID NO:4, produced by Sawady, 34 μ m), 2 μ l of 10 μ M arbitrary primer OPD-16 (sequence listing represented by SEQ ID NO:5) and 0.5 μ l of DNA polymerase Gene Taq were added to about 1/4 portion of the gel thus cut off, the resulting mixture was heated at 94°C for 3 minutes and then a total of 30 cycles of the reaction was carried out in which one cycle was comprised of the steps of 95°C for 15 seconds, 40°C for 2 minutes and 72°C for 1 minute, subsequently carrying out 5 minutes of the reaction at 72°C to complete PCR.

The resulting reaction solution was extracted with phenol-chloroform (1:1) and then with chloroform-isoamyl alcohol (24:1), subsequently carrying out ethanol precipitation. The resulting precipitation was dissolved in 10 μ l of TE buffer.

A 1 μ l portion of amplified fragment and 1 μ l of PCR fragment cloning vector pT7BlueT-Vector (manufactured by Novagen Inc.) were mixed and the amplified fragment was inserted into the plasmid using DNA ligation kit ver. 1 (manufactured by Takara Shuzo Co., Ltd.) according to the instructions of the kit. *E. coli* DH5 α (manufactured by Gibco BRL) was transformed with the ligated mixture to obtain an ampicillin resistant transformant. Plasmid DNA was isolated for the transformant strain according to a publicly known

method. A 0.3 ng portion of the plasmid DNA was dissolved into 19 μ l of distilled water, and 2.5 μ l of 10 x PCR buffer, 2 μ l of 2.5 mM dNTP, 0.3 μ l of 34 μ M anchor primer NC, 1 μ l of 10 μ M optional primer OPD-16 and 0.5 μ l of DNA polymerase Gene Taq were added for performing PCR under the same conditions reamplification of amplified fragment. Since the fragment of about 200 bp was amplified, it was confirmed that the amplified fragment had been inserted into the plasmid.

(3) Determination of amplified fragment nucleotide sequence

The nucleotide sequence of the amplified fragment was determined by means of DNA sequencer (manufactured by Parkin Elmer). For the nucleotide sequence determination, reagents and method supplied by Dye Primer Cycle Sequencing FS Ready Reaction Kit of Parkin Elmer were used according to the instructions of the kit. The thus obtained nucleotide sequence corresponded to the DNA sequence 1076 to 1261 in SEQ ID NO:1. Thus obtained nucleotide sequence was compared with the nucleotide sequence database GenBank. The nucleotide sequence corresponding to the concerned nucleotide sequence was not identified among nucleotide sequences in the database, so that it was considered as cDNA fragment of a novel gene. Then the nucleotide sequence

was compared with cDNA nucleotide sequence data base in the KG-1cDNA library, it was found to completely agree with a portion of cDNA nucleotide sequence of the gene KIAA0235, determining that KIAA0235 was a novel gene whose expression increases in the leukocyte of IgA nephropathy patients. As shown in SEQ ID NO:1, KIAA0235 was 5399 bp long and an open reading frame (ORF) composed of 850 amino acids exist therein. The amino acid sequence thereof is shown in SEQ ID NO:2. In the comparison of KIAA0235 nucleotide sequence with the database Genbank/EMBL, there are no identical nucleotide sequence, confirming that it concerns a novel gene cDNA. Moreover, when the amino acid sequence encoded by the cDNA ORF was compared with the database, it has shown a homology, at C terminal side, with the amino acid sequence of the pumilio gene [*Development*, 114, 221 (1992); *Cell*, 80, 747 (1995)] that is bound with mRNA of the hunchback gene derived from the mother, during the embryo development of *Drosophila*, and playing an important role in the formation of abdominal arthromere. It has also shown a homology of 82% with the amino acid sequence of the ORF of KIAA0099 [*DNA Research*, 2, 37 (1995)] already reported in the cDNA clone derived from this KG-1.

Example 3 Northern blot of KIAA0235 in human cell and various tissues

Next, Northern blot was carried out to determine the expression of mRNA of the novel gene KIAA0235 in human cell and tissues.

Using filters manufactured by Clontech blotting mRNA of human various tissues, the expression of mRNA of KIAA0235 in human various tissues was detected by means of Northern blot. Heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas mRNAs were blotted on the filter, Human MTN Blot. Spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral leukocyte mRNAs were blotted in the Human MTN Blot II. Concerning the cell, 2 µg of poly (A)⁺RNA obtained from human cervical carcinoma cell line, HeLa cell in the same manner as in Example 1 and poly (A)⁺RNA of KG-1 were applied to agarose gel electrophoresis, transferred to filter Biodyne A (manufactured by Paul Inc.), and KIAA0235 mRNA expression was detected by means of Northern blotting in the same manner. To use as probe, plasmid clone HA4677 containing KIAA0235 cDNA in the cDNA library prepared in Example 1 was cleaved by NotI (manufactured by Takara Shuzo Co., Ltd.) and HindIII (manufactured by Takara Shuzo Co., Ltd.) to purify KIAA0235 cDNA fragment. A 50 ng portion of this

fragment were ^{32}P labeled using $[\alpha\text{-}^{32}\text{P}]\text{dCTP}$ and BcaBEST labeling kit (manufactured by Takara Shuzo Co., Ltd.). Specific reagents and method of the labeling were complied with the instructions of the kit.

The filter was soaked in a hybridization solution [50% formaldehyde, 5 × SSC, 5 × Denhardt's solution (0.1% BSA, 0.1% ficol, 0.1% polyvinyl pyrrolidone, 0.25% SDS, 100 µg/ml of herring spermatozoa DNA which had been subjected to ultrasonic treatment and then denaturation (the process of seething in a microwave oven and chilled quickly in the ice was repeated 3 times), sealed and prehybridized overnight at 37°C. Next, the probe was denatured by seething in a microwave oven and chilling in the ice 3 times, added into the hybridization solution. The filter was soaked therein, sealed and hybridized overnight at 37°C.

The filter was taken out, washed by shaking in 1 × SSC containing 0.1% SDS at room temperature. Changing the solution, it was washed furthermore several times, then rinsed with 0.1 × SSC containing 0.5 SDS, and washed by shaking at 50°C for 1 hour in 0.1 × SSC containing 0.5% SDS. Finally, it was washed with 1 × SSC containing 0.1% SDS and dried in the air. The filter was overlaid on the imaging plate (manufactured by Fuji Photo Film Co., Ltd.) for conducting the

autoradiography for 4 hours, and analyzed with Bioimaging Analyzer BAS 2000 (manufactured by Fuji Photo Film Co., Ltd.). The results are shown in Fig. 1. Bands corresponding to mRNA of 2 different lengths, 5.5 kb and 6.8 kb, were detected in all tissues of heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral leukocyte. Therefore, it was confirmed that KIAA0235 was a gene expressing ubiquitously in respective tissue. Moreover, bands corresponding to mRNA of 2 different lengths, 5.5 kb and 6.8 kb, were similarly detected in KG-1 and HeLa cells, and the expression of KIAA0235 in both cells was confirmed.

Example 4 Detection of expression specificity of KIAA0235 by RT-PCR

Using single-stranded cDNA synthesis kit, Superscript Preamplification System (manufactured by BRLs), to 2 µg of total RNA from leukocyte of 5 IgA nephropathy patients and 5 healthy persons obtained in Example 2, single-stranded cDNA was synthesized by oligo dT primer supplied by the kit. Specific reagents and method were complied with the protocol attached to the kit. After the reaction, 399 µl of distilled water was

added to 21 μ l of reaction mixture to be 420 μ l as a whole, mRNA expression amount corresponding to each amplified fragment was measured by using 10 μ l thereof according to RT-PCR. Namely, 15.8 μ l of distilled water, 4 μ l of 10 \times PCR buffer, 3.2 μ l of 2.5 mM dNTP, 2 μ l of DMSO, 2 μ l of 10 μ M KIAA0235 specific 5'-side sense primer (SEQ ID NO:6), 2 μ l of 10 μ M KIAA0235 specific 3'-side antisense primer (SEQ ID NO:7) and 2 μ l of DNA polymerase GeneTaq diluted to 1 unit/ μ l were added to 10 μ l of leukocyte single-stranded cDNA, heated at 97°C for 5 minutes, chilled quickly in the ice for 5 minutes. Subsequently, the PCR (a total of 30 cycles of the reaction in which one cycle was composed of the steps of 95°C for 30 seconds, 65°C for 1 minute and 72°C for 2 minutes) was carried out.

In order to make a correction of the mRNA amount, with regard to glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene, a housekeeping gene, the similar reaction was carried out using a specific primer represented by SEQ ID NO:8 and NO:9, the mRNA expression amount of each gene was calibrated by the ratio to the expression amount of G3PDH mRNA, and then the average values of 5 IgA nephropathy patients and 5 healthy persons were compared. The results are shown in Fig. 2. It was confirmed that in the leukocyte of IgA nephropathy

patients, KIAA0235 has expressed 6.6 times more than in healthy persons.

While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.

SEQUENCE LISTING

SEQ ID NO:1
 SEQUENCE LENGTH: 5399
 SEQUENCE TYPE: nucleic acid
 STRANDEDNESS: double
 TOPOLOGY: linear
 MOLECULE TYPE: cDNA
 ORIGINAL SOURCE
 ORGANISM: human
 CELL LINE: KG-1

A	GAA	TTT	TCA	AAT	CCT	GAA	ACT	CAG	AAT	CTG	GAT	GCC	ATG	GAA	CAA	GTT	49
	Glu	Phe	Ser	Asn	Pro	Glu	Thr	Gln	Asn	Leu	Asp	Ala	Met	Glu	Gln	Val	
1				5				10						15			
GGT	CTG	GAA	TCC	TTA	CAG	TTT	GAC	TAT	CCT	GGT	AAT	CAG	GTA	CCA	ATG		97
Gly	Leu	Glu	Ser	Leu	Gln	Phe	Asp	Tyr	Pro	Gly	Asn	Gln	Val	Pro	Met		
	20						25					30					
GAC	TCT	TCA	GGA	GCT	ACT	GTA	GGC	CTT	TTT	GAC	TAC	AAT	TCC	CAG	CAG		145
Asp	Ser	Ser	Gly	Ala	Thr	Val	Gly	Leu	Phe	Asp	Tyr	Asn	Ser	Gln	Gln		
	35						40					45					
CAG	CTC	TTT	CAG	AGG	ACT	AAT	GCA	CTA	ACA	GTT	CAA	CAG	TTA	ACT	GCA		193
Gln	Leu	Phe	Gln	Arg	Thr	Asn	Ala	Leu	Thr	Val	Gln	Gln	Leu	Thr	Ala		
	50					55					60						
GCT	CAA	CAG	CAG	CAA	TAT	GCA	TTA	GCA	GCA	GCT	CAG	CAG	CCA	CAT	ATA		241
Ala	Gln	Gln	Gln	Gln	Tyr	Ala	Leu	Ala	Ala	Ala	Gln	Gln	Pro	His	Ile		
	65				70				75				80				
GCT	GGT	GTA	TTC	TCA	GCA	GGC	CTT	GCT	CCA	GCT	GCA	TTT	GTG	CCA	AAT		289
Ala	Gly	Val	Phe	Ser	Ala	Gly	Leu	Ala	Pro	Ala	Ala	Phe	Val	Pro	Asn		
			85					90				95					
CCA	TAC	ATT	ATT	AGT	GCT	GCT	CCT	CCA	GGG	ACC	GAT	CCG	TAT	ACT	GCA		337
Pro	Tyr	Ile	Ile	Ser	Ala	Ala	Pro	Pro	Gly	Thr	Asp	Pro	Tyr	Thr	Ala		
	100						105					110					
GCA	GGA	TTG	GCT	GCA	GCA	GCT	ACA	TTA	GCA	GGT	CCA	GCA	GTG	GTT	CCA		385
Ala	Gly	Leu	Ala	Ala	Ala	Ala	Thr	Leu	Ala	Gly	Pro	Ala	Val	Val	Pro		
	115						120					125					
CCT	CAG	TAT	TAC	GGC	GTT	CCA	TGG	GGG	GTG	TAT	CCA	GCC	AAC	TTA	TTT		433
Pro	Gln	Tyr	Tyr	Gly	Val	Pro	Trp	Gly	Val	Tyr	Pro	Ala	Asn	Leu	Phe		
	130					135					140						
CAG	CAG	CAA	GCT	GCA	GCT	GCG	GCA	AAT	AAC	ACA	GCC	AGT	CAG	CAA	GCA		481
Gln	Gln	Gln	Ala	Ala	Ala	Ala	Ala	Asn	Asn	Thr	Ala	Ser	Gln	Gln	Ala		
	145				150				155				160				
GCA	TCA	CAA	GCT	CAG	CCT	GGA	CAG	CAA	CAG	GTT	CTC	CGT	GCT	GGA	GCA		529
Ala	Ser	Gln	Ala	Gln	Pro	Gly	Gln	Gln	Gln	Val	Leu	Arg	Ala	Gly	Ala		
			165				170					175					
GGT	CAG	CGT	CCT	CTT	ACT	CCC	AAT	CAG	GGT	CAG	CAA	GGG	CAG	CAA	GCA		577
Gly	Gln	Arg	Pro	Leu	Thr	Pro	Asn	Gln	Gly	Gln	Gln	Gly	Gln	Gln	Ala		
			180				185					190					
GAA	TCA	CTT	GCG	GCA	GCT	GCA	GCA	AAT	CCA	ACA	TTG	GCT	TTT	GGT			625
Glu	Ser	Leu	Ala	Ala	Ala	Ala	Ala	Asn	Pro	Thr	Leu	Ala	Phe	Gly			
			195			200					205						
CAG	GGT	CTT	GCT	ACT	GGC	ATG	CCA	GGC	TAT	CAA	GTA	CTA	GCT	CCA	ACT		673

Gln	Gly	Leu	Ala	Thr	Gly	Met	Pro	Gly	Tyr	Gln	Val	Leu	Ala	Pro	Thr		
210						215					220						
GCC	TAT	TAT	GAT	CAG	ACT	GGT	GCC	TTA	GTG	GTT	GGC	CCT	GGA	GCA	AGG	721	
Ala	Tyr	Tyr	Asp	Gln	Thr	Gly	Ala	Leu	Val	Val	Gly	Pro	Gly	Ala	Arg		
225					230					235					240		
ACT	GGC	CTT	GGA	GCT	CCA	GTT	CGG	TTA	ATG	GCT	CCA	ACA	CCT	GTT	TTA	769	
Thr	Gly	Leu	Gly	Ala	Pro	Val	Arg	Leu	Met	Ala	Pro	Thr	Pro	Val	Leu		
				245					250						255		
ATT	AGT	TCA	GCA	GCA	GCA	CAA	GCT	GCA	GCA	GCA	GCA	GCA	GCT	GGA	GGA	817	
Ile	Ser	Ser	Ala	Ala	Ala	Gln	Ala	Ala	Ala	Ala	Ala	Ala	Ala	Gly	Gly		
			260					265					270				
ACT	GCA	AGT	AGC	CTT	ACA	GGC	AGC	ACA	AAT	GGT	CTG	TTT	CGG	CCA	ATT	865	
Thr	Ala	Ser	Ser	Leu	Thr	Gly	Ser	Thr	Asn	Gly	Leu	Phe	Arg	Pro	Ile		
		275					280					285					
GGC	ACT	CAG	CCA	CCA	CAG	CAG	CAG	CAA	CAG	CAG	CCA	AGC	ACT	AAT	CTG	913	
Gly	Thr	Gln	Pro	Pro	Gln	Gln	Gln	Gln	Gln	Gln	Pro	Ser	Thr	Asn	Leu		
	290				295						300						
CAA	TCT	AAT	TCA	TTT	TAT	GGA	AGC	AGT	TCT	TTG	ACT	AAT	AGC	TCC	CAG	961	
Gln	Ser	Asn	Ser	Phe	Tyr	Gly	Ser	Ser	Ser	Leu	Thr	Asn	Ser	Ser	Gln		
305					310					315					320		
AGT	AGT	TCT	TTA	TTT	TCT	CAT	GGA	CCT	GGT	CAA	CCT	GGA	AGT	ACA	TCT	1009	
Ser	Ser	Ser	Leu	Phe	Ser	His	Gly	Pro	Gly	Gln	Pro	Gly	Ser	Thr	Ser		
				325					330						335		
CTT	GGC	TTT	GGA	AGT	GGT	AAC	TCT	TTG	GGT	GCT	GCT	ATA	GGC	TCA	GCC	1057	
Leu	Gly	Phe	Gly	Ser	Gly	Asn	Ser	Leu	Gly	Ala	Ala	Ile	Gly	Ser	Ala		
			340				345					350					
CTC	AGT	GGA	TTT	GGT	TCA	TCA	GTT	GGC	AGT	TCT	GCA	AGT	AGT	AGT	GCC	1105	
Leu	Ser	Gly	Phe	Gly	Ser	Ser	Val	Gly	Ser	Ser	Ala	Ser	Ser	Ser	Ala		
		355					360					365					
ACA	AGG	AGA	GAG	TCT	CTA	TCT	ACT	AGC	TCT	GAC	TTG	TAC	AAA	AGA	TCT	1153	
Thr	Arg	Arg	Glu	Ser	Leu	Ser	Thr	Ser	Ser	Asp	Leu	Tyr	Lys	Arg	Ser		
	370				375						380						
AGT	AGC	AGC	CTA	GCA	CCC	ATA	GGG	CAA	CCA	TTT	TAC	AAT	AGT	CTG	GGA	1201	
Ser	Ser	Ser	Leu	Ala	Pro	Ile	Gly	Gln	Pro	Phe	Tyr	Asn	Ser	Leu	Gly		
385					390					395					400		
TTT	TCC	TCC	TCT	CCA	AGT	CCA	ATA	GGC	ATG	CCT	CTG	CCA	AGC	CAA	ACT	1249	
Phe	Ser	Ser	Ser	Pro	Ser	Pro	Ile	Gly	Met	Pro	Leu	Pro	Ser	Gln	Thr		
				405					410						415		
CCA	GGA	CAT	TCA	CTT	ACG	CCA	CCG	CCA	TCA	CTT	TCA	TCA	CAT	GGA	TCC	1297	
Pro	Gly	His	Ser	Leu	Thr	Pro	Pro	Pro	Ser	Leu	Ser	Ser	His	Gly	Ser		
			420					425					430				
TCA	TCC	AGT	TTG	CAT	TTA	GGA	GGA	CTG	ACA	AAT	GGT	AGT	GGT	CGA	TAT	1345	
Ser	Ser	Ser	Leu	His	Leu	Gly	Gly	Leu	Thr	Asn	Gly	Ser	Gly	Arg	Tyr		
		435					440					445					
ATC	TCT	GCA	GCA	CCT	GGA	GCA	GAA	GCA	AAA	TAT	CGA	AGT	GCT	TCA	AGC	1393	
Ile	Ser	Ala	Ala	Pro	Gly	Ala	Glu	Ala	Lys	Tyr	Arg	Ser	Ala	Ser	Ser		
		450				455					460						
ACT	TCC	AGT	CTA	TTT	AGC	TCC	AGC	AGC	CAG	CTC	TTT	CCT	CCT	TCC	CGG	1441	
Thr	Ser	Ser	Leu	Phe	Ser	Ser	Ser	Ser	Gln	Leu	Phe	Pro	Pro	Ser	Arg		
465					470					475					480		
CTT	CGG	TAT	AAT	AGG	TCT	GAT	ATT	ATG	CCT	TCT	GGC	CGC	AGT	AGA	TTA	1489	

Leu	Arg	Tyr	Asn	Arg	Ser	Asp	Ile	Met	Pro	Ser	Gly	Arg	Ser	Arg	Leu		
				485					490					495			
TTG	GAA	GAT	TTC	AGA	AAC	AAC	CGC	TTC	CCA	AAC	CTT	CAG	CTT	AGA	GAC	1537	
Leu	Glu	Asp	Phe	Arg	Asn	Asn	Arg	Phe	Pro	Asn	Leu	Gln	Leu	Arg	Asp		
			500					505					510				
TTG	ATT	GGA	CAT	ATA	GTT	GAG	TTT	TCT	CAA	GAC	CAG	CAT	GGT	TCT	AGA	1585	
Leu	Ile	Gly	His	Ile	Val	Glu	Phe	Ser	Gln	Asp	Gln	His	Gly	Ser	Arg		
			515				520					525					
TTC	ATA	CAG	CAA	AAA	CTA	GAG	AGA	GCT	ACT	CCA	GCT	GAG	CGA	CAG	ATG	1633	
Phe	Ile	Gln	Gln	Lys	Leu	Glu	Arg	Ala	Thr	Pro	Ala	Glu	Arg	Gln	Met		
			530				535					540					
GTA	TTT	AAT	GAA	ATT	CTG	CAA	GCA	GCC	TAT	CAA	TTA	ATG	ACT	GAT	GTT	1681	
Val	Phe	Asn	Glu	Ile	Leu	Gln	Ala	Ala	Tyr	Gln	Leu	Met	Thr	Asp	Val		
			545		550					555					560		
TTT	GGC	AAC	TAT	GTT	ATA	CAG	AAG	TTT	TTT	GAG	TTT	GGG	AGT	CTG	GAT	1729	
Phe	Gly	Asn	Tyr	Val	Ile	Gln	Lys	Phe	Phe	Glu	Phe	Gly	Ser	Leu	Asp		
			565					570							575		
CAA	AAA	TTA	GCC	CTG	GCT	ACT	CGT	ATT	CGT	GGT	CAT	GTT	CTA	CCC	TTA	1777	
Gln	Lys	Leu	Ala	Leu	Ala	Thr	Arg	Ile	Arg	Gly	His	Val	Leu	Pro	Leu		
			580					585					590				
GCC	TTG	CAG	ATG	TAT	GGC	TGC	CGC	GTT	ATT	CAG	AAA	GCA	TTA	GAA	TCT	1825	
Ala	Leu	Gln	Met	Tyr	Gly	Cys	Arg	Val	Ile	Gln	Lys	Ala	Leu	Glu	Ser		
			595				600					605					
ATT	TCT	TCT	GAC	CAG	CAG	AGT	GAA	ATG	GTA	AAG	GAG	CTG	GAT	GGT	CAT	1873	
Ile	Ser	Ser	Asp	Gln	Gln	Ser	Glu	Met	Val	Lys	Glu	Leu	Asp	Gly	His		
			610			615					620						
GTG	CTC	AAA	TGT	GTG	AAA	GAT	CAG	AAT	GGA	AAC	CAT	GTT	GTA	CAA	AAA	1921	
Val	Leu	Lys	Cys	Val	Lys	Asp	Gln	Asn	Gly	Asn	His	Val	Val	Gln	Lys		
			625		630					635					640		
TGT	ATC	GAA	TGT	GTT	CAG	CCA	CAG	TCA	CTA	CAG	TTC	ATC	ATT	GAT	GCT	1969	
Cys	Ile	Glu	Cys	Val	Gln	Pro	Gln	Ser	Leu	Gln	Phe	Ile	Ile	Asp	Ala		
			645					650							655		
TTC	AAG	GGA	CAA	GTA	TTT	GTG	CTT	TCA	ACT	CAT	CCT	TAT	GGC	TGC	AGA	2017	
Phe	Lys	Gly	Gln	Val	Phe	Val	Leu	Ser	Thr	His	Pro	Tyr	Gly	Cys	Arg		
			660					665					670				
GTA	ATT	CAG	CGC	ATC	CTA	GAG	CAT	TGC	ACT	GCA	GAA	CAG	ACC	TTA	CCT	2065	
Val	Ile	Gln	Arg	Ile	Leu	Glu	His	Cys	Thr	Ala	Glu	Gln	Thr	Leu	Pro		
			675				680					685					
ATC	TTA	GAA	GAA	CTC	CAC	CAA	CAT	ACA	GAG	CAG	TTG	GTA	CAG	GAT	CAG	2113	
Ile	Leu	Glu	Glu	Leu	His	Gln	His	Thr	Glu	Gln	Leu	Val	Gln	Asp	Gln		
			690			695					700						
TAT	GGC	AAT	TAT	GTT	ATT	CAG	CAT	GTA	CTG	GAA	CAC	GGT	CGA	CCT	GAA	2161	
Tyr	Gly	Asn	Tyr	Val	Ile	Gln	His	Val	Leu	Glu	His	Gly	Arg	Pro	Glu		
			705		710					715					720		
GAC	AAG	AGC	AAA	ATT	GTT	TCC	GAA	ATC	AGG	GGA	AAG	GTT	TTA	GCC	CTG	2209	
Asp	Lys	Ser	Lys	Ile	Val	Ser	Glu	Ile	Arg	Gly	Lys	Val	Leu	Ala	Leu		
			725					730							735		
AGT	CAA	CAC	AAA	TTT	GCC	AGC	AAT	GTA	GTA	GAA	AAG	TGT	GTT	ACT	CAT	2257	
Ser	Gln	His	Lys	Phe	Ala	Ser	Asn	Val	Val	Glu	Lys	Cys	Val	Thr	His		
			740					745							750		
GCC	TCC	CGT	GCT	GAG	AGA	GCT	TTA	CTG	ATT	GAC	GAG	GTT	TGC	TGC	CAG	2305	

Ala Ser Arg Ala Glu Arg Ala Leu Leu Ile Asp Glu Val Cys Cys Gln
755 760 765
AAT GAT GGT CCT CAC AGT GCC TTA TAC ACC ATG ATG AAG GAC CAG TAT 2353
Asn Asp Gly Pro His Ser Ala Leu Tyr Thr Met Met Lys Asp Gln Tyr
770 775 780
GCC AAT TAC GTG GTT CAA AAG ATG ATT GAT ATG GCT GAA CCT GCT CAG 2401
Ala Asn Tyr Val Val Gln Lys Met Ile Asp Met Ala Glu Pro Ala Gln
785 790 795 800
AGA AAG ATA ATC ATG CAC AAG ATT CGA CCT CAC ATT ACT ACT TTG CGC 2449
Arg Lys Ile Ile Met His Lys Ile Arg Pro His Ile Thr Thr Leu Arg
805 810 815
AAA TAC ACA TAC GGG AAG CAT ATA CTG GCC AAG TTG GAA AAG TAT TAT 2497
Lys Tyr Thr Tyr Gly Lys His Ile Leu Ala Lys Leu Glu Lys Tyr Tyr
820 825 830
TTG AAG AAT AGC CCG GAC CTA GGA CCT ATT GGA GGA CCA CCA AAT GGA 2545
Leu Lys Asn Ser Pro Asp Leu Gly Pro Ile Gly Gly Pro Pro Asn Gly
835 840 845
ATG CTG TAAATTACAG GAGCAAGAGA AAGAAGATAA TTTAACCATG TGAAAAGAAT 2601
Met Leu
850
TTTTTTGTGC GTGAATTATC AAAACACAAC TCAACTATGA ATCTTCAATT TTTTTTTAAA 2661
GCAAAACTAT TTATTGACTT TATTCATCCA TTTGTAAATT TTTTAAGGTT CTTGTGTATA 2771
TTTGGGGGGT GGGGGATGAA TTATAAATTA TATTCAGCCC TGAGTGGAGA CCTATCAGAT 2781
TGGATTGCTG GCAAAGCACA GAATGCCTGT ATATGATGTA ACTGTATCAA AAATAAAAAG 2841
CTGTACATA TTTTGTAAT TTTTACCTTG TAAAGTCACA AAAATAGTTT TTAAAGGAAA 2901
AAGTACAGTA TTCTTTTAAT AAACCTGGCTC ACAGTCTGGT AGGTCTACAA CCCCATAGCA 2961
CAACAGGTTT ATAGAGATGT ATATAGAATT ATAGTCCTTA TTTTTTTCCT TTGCGTGAAA 3021
CCTTTTATAA CAGATTAACA ATCAACTGCA TAAATATTAT TAATATTTTA AAAAGAGTTA 3081
AGTTGTATTT TGATAATTCA CAACTATCA TGCAAATAAC GAGTAAGTAG ACAAGAATAA 3141
AGTGGTTTGA GATGAAAAGA ACCTAACATT ATTTACAGTA GATGTGGTTT TAATACAATT 3201
ACTGCCCTAA AATGTCTCTG GCAATGTACA GAAATATTGT ATATACTTAC ATATGTAATT 3261
GTTGTAAGAG TTAAATACAA AATCATGGTG ACACCTCCAA TTAAGTGCAC TAAATGAAAA 3321
GTAAAGTCAC TTATTAACCTT TTCAGTTTGG TTTGCAATGA GAAAGAGTGG AAATTTGTAT 3381
TTTGTTTTGC TTATAGAATT ACAGACATGT TGAGGAAGTG TTGAGCTTTA TTTTGCTTTT 3441
TCATAGAGGC AGAAAGTAGG AACCAGATAG AGATGAAAAG GGGCCACTGA AAAGTGAATT 3501
TGATAGCTCA GCATTTAAGC ATGATTACAT ATTCAGATAG CTCTTTTTGC TTTCTATAAA 3561
TATATGCATT GTGTGTGTAG TAATAGATGT AAGTTTACAC TTTGAAAGGA AATCTTGTTT 3621
CAATGTTTAT TATAAAAGCC TTGCTAATTT AGTAGTGATG CTTTCCTTGG TTGTACAGGT 3681
GTACATTTGT AAACCTTCAT GCTGTAAATG GAATTTGTTT TATCTCTTTG GGATACATTT 3741
GCATTTTAGT GTACATTTAC GTCCCTGCCC TCTTTGACCT GGCAATATAG TGTGTATATA 3801
TGTAATTTTA TTTCTCCAAA TCGAGAGTGA TTTTTTAAAA ATTTTTTATC TTTATATGGT 3861
TTCAGAAGTA TGAACAGCT TTCTTTTAT TATTGTGAGA TCATTTTGTT TTATAACATA 3921
GTTGTTGACT GTTAATATGG ACCTGCTAGA ATTTGGATCA CTTTCAATTG AAGTCAGGGT 3981
ATTGTGCATA ATAGAAAGTA TTGGACTGAG ATATTTGGTT ACCATGGAGG CCAATGCTTT 4041
TTTCATCTTA TTAAATGTGA TGTGACTTTT TTCTTTGTAC AGAAGAGTAC TGTATTTTTG 4101
AATAGCCTAC TCCCAAGTAA GAGCAAATCT GTATGATAAC ATTTTTTCCT CTGGACATAA 4161
GACATAACAG TAACACGATG TACATTTACA AGCGGCCTTA TGTACATTTT CCAACAATCT 4221
TTTTAAGGCA AAATTGTGAC CATATGTGTA TAATTTAAAT CGTTTTTAAT CCTTGCCTA 4281
TGAAAATATT TTGGAAAAAA ACTTGCTGTG TATATTCAGT TTCTGAAAGA TAAAGAAAGT 4341
GCTTTGTATT TTGTTGAAGT CAGTATTTTG TATAAACATT TATGTTGACC CACTTATGTT 4401
CAGTGCTGAA AACTAAAATG AACATGCTAT TCTGTCAGCT GAATATGGAA GAGATCTTTT 4461

TTTACTAGAG ATCTGCAGAA GAAACGCAAT CTTCTGAGCA CAATATGGAA TCTAAAGGTT 4521
 TTATCACTTA GTTGTTCATA TTATGAACCT AAAAATAATG GCATAAAGTT TGGGGATGCC 4581
 AGGCATACTT TTTCATGTTT GGTGTTGAGT TATTTTACTT TTCTAACCCA ACATTCCTTG 4641
 GTGAGACCAT TAAATCCAAA CACTTGTCAC CGTTCCTTCT CATAGTCACT CTGGGTCATC 4701
 AGCATGTCCC AGTCACTGCA GCAACGCCTT GTGTTTGTTT CATTTTTTTA AAACCCACAC 4761
 AAAGCCGCTG TCTCACTTTT TCCTACTTTA CCAACCTCAG AGTATTTTCGG CCCGTATCGA 4821
 ACTTTTGTTT TCAGTATCAG CCCATGGTTT CAGGATCAAA GCTGTCATGT TGGAGATTGG 4881
 TAATGGCTTT CCTGTCTTTG TACAGTTGAA TTCCTAGTCT TCCTTCATCC TTGCCCTCTG 4941
 TTGGCACAGG CATTATCTCT GCAATTTTATG AAAATGACAA GTAGAGAATA CTACATTGAG 5001
 AACTAAACC CTCTTCTTGG GGTCCCTGATA CTCATTCCCA TTTGTCCCAG TGCTGACAAC 5061
 CCAATCTTCC CAATACTTTC AGGCCTGCTC TACAAAAGTA CCTGTTCTTG TAGAAATTTT 5121
 ACAGTCTGCC ATTTTGGGTG CCCACCCCAA TTTTACCTT TTAGTAAGTT GGCATGAAAT 5181
 TTTGGTAAAA TCTGAAAATC ACATTTTCTG ATAAAACAAT TGGGCAAAAC TACCTAGGCT 5241
 TTAATCTTGA GTGTCTCCTT TTGATAGGGA TTGTTTCTGG ACCAGTTTGT CTAAGTCCCTG 5301
 GCTCTTATTG GTTCATATGA AATAATGTGA ACTTCACTTC TTTGTATATT ATGTATAAAT 5361
 TAGAAAATGA AAAATGTGTG AATAACATTG TATGAAAT 5399

SEQ ID NO:2

SEQUENCE LENGTH: 850

SEQUENCE TYPE: amino acid

TOPOLOGY: linear

MOLECULE TYPE: protein

ORIGINAL SOURCE

ORGANISM: human

CELL LINE: KG-1

Glu	Phe	Ser	Asn	Pro	Glu	Thr	Gln	Asn	Leu	Asp	Ala	Met	Glu	Gln	Val	1	5	10	15
Gly	Leu	Glu	Ser	Leu	Gln	Phe	Asp	Tyr	Pro	Gly	Asn	Gln	Val	Pro	Met	20	25	30	
Asp	Ser	Ser	Gly	Ala	Thr	Val	Gly	Leu	Phe	Asp	Tyr	Asn	Ser	Gln	Gln	35	40	45	
Gln	Leu	Phe	Gln	Arg	Thr	Asn	Ala	Leu	Thr	Val	Gln	Gln	Leu	Thr	Ala	50	55	60	
Ala	Gln	Gln	Gln	Gln	Tyr	Ala	Leu	Ala	Ala	Ala	Gln	Gln	Pro	His	Ile	65	70	75	80
Ala	Gly	Val	Phe	Ser	Ala	Gly	Leu	Ala	Pro	Ala	Ala	Phe	Val	Pro	Asn	85	90	95	
Pro	Tyr	Ile	Ile	Ser	Ala	Ala	Pro	Pro	Gly	Thr	Asp	Pro	Tyr	Thr	Ala	100	105	110	
Ala	Gly	Leu	Ala	Ala	Ala	Ala	Thr	Leu	Ala	Gly	Pro	Ala	Val	Val	Pro	115	120	125	
Pro	Gln	Tyr	Tyr	Gly	Val	Pro	Trp	Gly	Val	Tyr	Pro	Ala	Asn	Leu	Phe	130	135	140	
Gln	Gln	Gln	Ala	Ala	Ala	Ala	Asn	Asn	Thr	Ala	Ser	Gln	Gln	Ala		145	150	155	160
Ala	Ser	Gln	Ala	Gln	Pro	Gly	Gln	Gln	Gln	Val	Leu	Arg	Ala	Gly	Ala	165	170	175	
Gly	Gln	Arg	Pro	Leu	Thr	Pro	Asn	Gln	Gly	Gln	Gln	Gly	Gln	Gln	Ala	180	185	190	
Glu	Ser	Leu	Ala	Ala	Ala	Ala	Ala	Asn	Pro	Thr	Leu	Ala	Phe	Gly					

[illegible]

```

SEQ ID NO:3
SEQUENCE LENGTH: 50
SEQUENCE TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid, synthesized DNA
SEQUENCE DESCRIPTION
CTCTAGAGGC GGCCGCTTTT TTTTTTTTTT TTTTTTTTTT TTTTTTTTTT

```

```

SEQ ID NO:4
SEQUENCE LENGTH: 17
SEQUENCE TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid, synthesized DNA
SEQUENCE DESCRIPTION
GTTTTTTTTTT TTTTTC

```

SEQ ID NO:5
 SEQUENCE LENGTH: 10
 SEQUENCE TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid, synthesized DNA
 SEQUENCE DESCRIPTION
 AGGGCGTAAG 10

SEQ ID NO:6
 SEQUENCE LENGTH: 22
 SEQUENCE TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid, synthesized DNA
 SEQUENCE DESCRIPTION
 GCATGCCTAT TGGACTTGGG GA 22

SEQ ID NO:7
 SEQUENCE LENGTH: 24
 SEQUENCE TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid, synthesized DNA
 SEQUENCE DESCRIPTION
 GTTGGCAGTT CTGCAAGTAG TAGT 24

SEQ ID NO:8
 SEQUENCE LENGTH: 22
 SEQUENCE TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid, synthesized DNA
 SEQUENCE DESCRIPTION
 CCCATCACCA TCTCCAGGA GC 22

SEQ ID NO:9
 SEQUENCE LENGTH: 26
 SEQUENCE TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid, synthesized DNA
 SEQUENCE DESCRIPTION
 TTCACCACCT TCTTGATGTC ATCATA 26

WHAT IS CLAIMED IS:

1. A protein comprising the amino acid sequence represented by SEQ ID NO:2.

2. A DNA encoding the protein according to claim 1.

3. The DNA according to claim 2, which comprises the nucleotide sequence represented by SEQ ID NO:1.

4. A DNA which hybridizes with the DNA comprising the nucleotide sequence according to claim 3 under stringent conditions.

5. A recombinant DNA which comprises the DNA according to any one of claims 2 to 4 and a vector.

6. A transformant obtained by introducing the recombinant DNA according to claim 5 into a host cell.

7. A process for producing a protein, comprising: culturing the transformant according to claim 6 in a medium to produce and accumulate the protein according to claim in the culture; and recovering said protein from the resulting culture.

8. An oligonucleotide comprising a portion of the nucleotide sequence of the DNA according to any one of claims 2 to 4.

9. An oligonucleotide comprising a portion of a nucleotide sequence complementary to the DNA according to any one of claims 2 to 4.

10. A method for detecting mRNA derived from the protein according to claim 1, comprising using the oligonucleotide according to claim 8.

11. A method for detecting mRNA derived from the protein according to claim 1, comprising using the oligonucleotide according to claim 9.

12. An IgA nephropathy diagnostic agent comprising the oligonucleotide according to claim 8.

13. An IgA nephropathy diagnostic agent comprising the oligonucleotide according to claim 9.

14. A method for inhibiting expression of the protein according to claim 1, comprising using the oligonucleotide according to claim 8.

15. A method for inhibiting expression of the protein according to claim 1, comprising using the oligonucleotide according to claim 9.

16. An IgA nephropathy therapeutic agent comprising the oligonucleotide according to claim 8.

17. An IgA nephropathy therapeutic agent comprising the oligonucleotide according to claim 9.

18. An antibody which specifically reacts with the protein according to claim 1.

19. A method for immunologically detecting the protein according to claim 1, comprising using the antibody according to claim 18.

20. An IgA nephropathy diagnostic agent comprising the antibody according to claim 18.

21. An IgA nephropathy therapeutic agent comprising the antibody according to claim 18.

ABSTRACT

The present invention relates to a novel protein isolated from the leukocyte of IgA nephropathy patients, and DNA encoding the protein. It also relates to an oligonucleotide based on the nucleotide sequence complementary with the DNA, an antibody which specifically reacts with the protein and, furthermore, diagnostic and therapeutic drugs of IgA nephropathy comprising it.

FIG. 1





FIG. 2



**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR C-I-P PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled NOVEL PROTEIN

_____, the specification of which

☒ attached hereto. ☐ was filed on _____
as Application No. _____ and was amended on _____
(if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Country	Application No.	Filed (Day/Mo./Yr.)	(Yes/No) Priority Claimed
Japan	Hei 8-325752	5 December 1996	Yes

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application No.	Filed (Day/Mo./Yr.)	Status (Patented/Pending/Abandoned)
PCT/JP97/04469	05/12/97	Pending

I hereby appoint the practitioners associated with the firm and Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to the address associated with that Customer Number:

FITZPATRICK, CELLA, HARPER & SCINTO
Customer Number: 05514

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

COMBINED DECLARATION AND POWER OF ATTORNEY
FOR C-I-P PATENT APPLICATION
(Page 2)

Full Name of Sole or First Inventor Tetsuyoshi Ishiwata

Inventor's signature _____

Date _____ Citizen/Subject of Japan

Residence 4-17-9, Morino, Machida-shi, Tokyo 194 Japan

Post Office Address _____

Full Name of Second Joint Inventor, if any Mikiko Sakurada

Second Inventor's signature _____

Date _____ Citizen/Subject of _____

Residence 5220 Fiore Terrace #213, San Diego, CA 92122

Post Office Address _____

Full Name of Third Joint Inventor, if any Ayako Nishimura

Third Inventor's signature _____

Date _____ Citizen/Subject of Japan

Residence 1-18-11, Miyasaka, Setagaya-ku, Tokyo 156 Japan

Post Office Address _____

Full Name of Fourth Joint Inventor, if any Satoshi Nakagawa

Fourth Inventor's signature _____

Date _____ Citizen/Subject of Japan

Residence 3-9-9, Naka-machi, Machida-shi, Tokyo 194 Japan

Post Office Address _____

Full Name of Fifth Joint Inventor, if any Tetsuro Kuga

Fifth Inventor's signature _____

Date _____ Citizen/Subject of Japan

Residence 3-9-13, Naka-machi, Machida-shi, Tokyo 194 Japan

Post Office Address _____

Full Name of Sixth Joint Inventor, if any Tatsunari Nishi

Sixth Inventor's signature _____

Date _____ Citizen/Subject of Japan

Residence 39-15, Higashimine-machi, Ohta-ku, Tokyo 145 Japan

Post Office Address _____

**COMBINED DECLARATION AND POWER OF ATTORNEY
FOR C-I-P PATENT APPLICATION**
(Page 3)

Full Name of Seventh Joint Inventor, if any Nobuo Nomura

Sixth Inventor's signature _____

Date _____ Citizen/Subject of Japan

Residence 5-2-11 Yahatadai, Kisarazu-shi, Chiba 292 Japan

Post Office Address _____

Full Name of Eighth Joint Inventor, if any Takahiro Nagase

Sixth Inventor's signature _____

Date _____ Citizen/Subject of Japan

Residence 5-1-26, Kiyomidaiminami, Kisarazu-shi, Chiba 292 Japan

Post Office Address _____

Full Name of Ninth Joint Inventor, if any Shigemasa Sawada

Sixth Inventor's signature _____

Date _____ Citizen/Subject of Japan

Residence 2-15-32, Kichijojihoncho, Musashino-shi, Tokyo 180 Japan

Post Office Address _____

Full Name of Tenth Joint Inventor, if any Masami Takei

Sixth Inventor's signature _____

Date _____ Citizen/Subject of Japan

Residence 124-140, Aoyagi, Sayama-shi, Saitama 350-13 Japan

Post Office Address _____

F508\A610749\ac